Biolipox is commited to world-leading research on arachidonic acid and its effects on inflammatory diseases - particularly asthma, COPD, allergies and pain.
Biolipox was founded by two professors from Karolinska Institutet in June 2000 after the discovery of a new family of arachidonic acid products with inflammatory effects - eoxins. Biolipox is a research-intense pharmaceutical company that develops new treatments for inflammatory diseases. These include major and growing widespread diseases such as asthma, COPD (also called smokersī disease), rhinitis (hay fever) and inflammatory and rheumatic pain. Biolipox is deepening its understanding in arachidonic acid and its role in various inflammatory processes. Biolipox's mission is to apply its leading research and development expertise to the development of new market-leading drugs for the treatment of inflammatory diseases, in particular, asthma, COPD, rhinitis, pain and arthritis.
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Senior management
To view this information, you must subscribe to Partneringtools.
Board of directors
To view this information, you must subscribe to Partneringtools.
Head office
To view this information, you must subscribe to Partneringtools.